Rhythm Pharmaceuticals Inc - Asset Resilience Ratio
Rhythm Pharmaceuticals Inc (RYTM) has an Asset Resilience Ratio of 69.55% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Rhythm Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check RYTM strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Rhythm Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Rhythm Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $334.65 Million | 69.55% |
| Total Liquid Assets | $334.65 Million | 69.55% |
Asset Resilience Insights
- Very High Liquidity: Rhythm Pharmaceuticals Inc maintains exceptional liquid asset reserves at 69.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rhythm Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Rhythm Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Rhythm Pharmaceuticals Inc (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Rhythm Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 69.55% | $334.65 Million | $481.19 Million | +10.55pp |
| 2024-12-31 | 59.00% | $231.43 Million | $392.27 Million | -5.85pp |
| 2023-12-31 | 64.84% | $215.76 Million | $332.75 Million | +11.09pp |
| 2022-12-31 | 53.76% | $205.61 Million | $382.48 Million | -17.74pp |
| 2021-12-31 | 71.50% | $235.61 Million | $329.52 Million | +33.04pp |
| 2020-12-31 | 38.45% | $71.94 Million | $187.07 Million | -36.15pp |
| 2019-12-31 | 74.60% | $230.16 Million | $308.52 Million | -3.23pp |
| 2018-12-31 | 77.83% | $202.52 Million | $260.21 Million | +2.80pp |
| 2017-12-31 | 75.03% | $113.85 Million | $151.74 Million | +42.64pp |
| 2016-12-31 | 32.39% | $4.00 Million | $12.34 Million | -24.78pp |
| 2013-12-31 | 57.18% | $10.40 Million | $18.19 Million | +29.32pp |
| 2012-12-31 | 27.85% | $5.27 Million | $18.92 Million | -- |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more